- Home
- ADCT
ADCT
ADC Therapeutics SA
as 05-30-2025 4:00pm EST
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
| Founded: | 2011 | Country: | Switzerland |
| Employees: | N/A | City: | EPALINGES |
| Market Cap: | 241.0M | IPO Year: | 2020 |
| Target Price: | $7.75 | AVG Volume (30 days): | 694.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.05 - $4.13 | Next Earning Date: | 05-14-2025 |
| Revenue: | $75,817,000 | Revenue Growth: | 10.49% |
| Revenue Growth (this year): | 9.19% | Revenue Growth (next year): | 16.27% |
Latest ADC Therapeutics SA News
ADCT Breaking Stock News: Dive into ADCT Ticker-Specific Updates for Smart Investing
Pharma Voice
2 days ago
AbbVie’s ADC win shows how pharma can break through in solid tumors
Clinical Trials Arena
17 days ago
ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data
PR Newswire
17 days ago
ADC Therapeutics to Present at Upcoming Investor Conferences
Zacks
18 days ago
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates
PR Newswire
18 days ago
ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update
PR Newswire
18 days ago
ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)
GuruFocus.com
19 days ago
What To Expect From ADC Therapeutics SA (ADCT) Q1 2025 Earnings
Zacks
23 days ago
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates
Compare ADCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADCT ADC Therapeutics SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.